Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.93 |
| ▸ | ACE | P12821 | 1/20 | 0.93 |
| ▸ | HTR2A | P28223 | 1/20 | 0.93 |
| ▸ | FAP | Q12884 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitagliptin SCHEMBL16227221 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1933943 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL16227400 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL16227491 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1935052 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL14127924 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL16227169 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL2388619 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL877068 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL15768042 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604744-B2 | Engineered transaminase polypeptides for industrial biocatalysis | CODEXIS, INC. (US) | 2020-03-31 | — | — | US | claimed |
| EP-2961844-B1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | CODEXIS INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-20180223265-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2018-08-09 | — | — | US | claimed |
| US-9963685-B2 | Engineered transaminase polypeptides for industrial biocatalysis | CODEXIS, INC. (US) | 2018-05-08 | — | — | US | claimed |
| US-20170175090-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-06-22 | — | — | US | claimed |
| US-9617573-B2 | Engineered transaminase polypeptides for industrial biocatalysis | CODEXIS, INC. (US) | 2017-04-11 | — | — | US | claimed |
| US-20160002688-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-01-07 | — | — | US | claimed |
| US-8889380-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2014-11-18 | — | — | US | claimed |
| US-8471016-B2 | Process for the preparation of chiral beta amino carboxamide derivatives | SUN PHARMACEUTICAL INDUSTRIES LTD. | 2013-06-25 | — | — | US | claimed |
| US-20130041150-A1 | PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO CARBOXAMIDE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2013-02-14 | — | — | US | claimed |
| US-20120329108-A1 | Transaminase Biocatalysts | CODEXIS, INC. (US) | 2012-12-27 | — | — | US | claimed |
| US-20100285541-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250340853-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | CODEXIS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12371678-B2 | Engineered transaminase polypeptides for industrial biocatalysis | CODEXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12344874-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | MERCK SHARP & DOHME LLC | 2007-12-06 | — | — | US | disclosed |
| US-20070141145-A1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMALN LTD. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070021430-A1 | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO., INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285541-A1 | TRANSAMINASE BIOCATALYSTS | GOT1, GOT2, ENPEP | DPP4 80/4885DPP8 58/4885DPP9 46/4885 |
| US-20250340853-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | GOT1, TKT, OAT | DPP4 213/4885DPP8 169/4885DPP9 128/4885 |
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20070141145-A1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | CD44, HDGF, MTDH | DPP4 3908/4885DPP8 3958/4885DPP9 3555/4885 |
| US-20170175090-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | GOT1, TKT, OAT | DPP4 213/4885DPP8 169/4885DPP9 128/4885 |
| US-12371678-B2 | Engineered transaminase polypeptides for industrial biocatalysis | GOT1, TKT, OAT | DPP4 213/4885DPP8 169/4885DPP9 128/4885 |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | XDH, AGXT, PEPD | DPP4 145/4885DPP8 94/4885DPP9 88/4885 |
| US-20130041150-A1 | PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO CARBOXAMIDE DERIVATIVES | BCAT2, BCAT1, SUCLA2 | DPP4 885/4885DPP8 1777/4885DPP9 931/4885 |
| US-20070021430-A1 | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20180223265-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | GOT1, TKT, OAT | DPP4 213/4885DPP8 169/4885DPP9 128/4885 |
| US-10604744-B2 | Engineered transaminase polypeptides for industrial biocatalysis | GOT1, TKT, OAT | DPP4 213/4885DPP8 169/4885DPP9 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.